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Scott L. Stevens, MD, Michael B. Freeman, MD, and Mitchell H. Goldman, MD, Knoxville, Tenn
Objective: Postmenopausal women receiving hormone replacement therapy (HRT) have been reported to have more
adverse outcomes after vascular reconstructions, including increased intimal hyperplasia development and bypass graft
failure. HRTmay be affecting the pathway contributing to intimal hyperplasia. An important component of this pathway
involves matrix metalloproteinases (MMPs), implicated in vascular remodeling due to their ability to degrade compo-
nents of the extracellular matrix. We hypothesize that estrogen (Est) and progesterone (Prog) upregulate the MMP
pathway in vascular smooth muscle cells (VSMCs) thereby increasing MMP activity and function.
Methods and Results: VSMCs were incubated with Est (5 ng/mL), Prog (50 ng/mL), Est  Prog combination
(Est/Prog), and/or doxycycline (40 g/mL; Doxy). Using reverse transcriptase polymerase chain reaction (RT-PCR)
analysis we have previously shown membrane type 1-MMP (MT1-MMP) messenger ribonucleic acid (mRNA) levels are
significantly increased by Est. Here, Western blot analyses indicated MT1-MMP and MMP-2 protein levels, not tissue
inhibitor of MMP-2 (TIMP-2), were increased in response to Est and Est/Prog (P< .05 vs control). In-gel zymography
revealed that Est and Est/Prog resulted in increased MMP-2 activity (hormone groups, P < .05 vs control) with no
significant difference among the hormone groups. VSMC migration was increased by 45  14% in response to Est (P <
.05 vs control), as measured using a modified Boyden chamber assay. Doxycycline significantly inhibited basal and
Est/Prog-stimulated increases in MMP-2 activity (P< .05 vs control; P< .05 vs hormone groups), and partially blocked
basal and hormonally stimulated migration (P < .05 vs control and Est).
Conclusion: Estrogen and progesterone affects the MMP pathway by increasing MMP-2 enzymatic activity, possibly via
the upregulation of MT1-MMP expression without a corresponding increase in TIMP expression. This increased
collagenase activity increases VSMC motility and their ability to migrate through a collagen type IV lattice. Est/Prog
upregulation of MT1-MMP may contribute to the adverse effect of HRT on vascular interventions. ( J Vasc Surg 2009;
49:185-91.)
Clinical Relevance: Postmenopausal women receiving HRT have more adverse outcomes after vascular reconstructions,
including intimal hyperplasia, restenosis, and decreased graft patency.MMPs play a major role in vascular remodeling due
to their degradation of components of the basement membrane separating vascular cell layers. Specifically, MMP-2 has a
strong affinity for collagen type IV degradation, and MT1-MMP is a transmembrane protein known to activate MMP-2
by proteolytic cleavage. Here we provide strong evidence forMT1-MMP’s role in increasedMMP-2 activity and increased
cellular migration in VSMCs exposed to estrogen and progesterone. Manipulations of the MMP pathway specifically
targeting MT1-MMP expression at the time of vascular interventions may improve outcomes in females receiving HRT.Atherosclerotic disease in the coronary and peripheral
arterial vasculature is a leading cause of morbidity and
mortality in the United States.1 The incidence of both
cardiovascular disease and noncardiac vascular disease is
greater in men compared with age-matched premenopausal
women,2,3 and there is a long-standing hypothesis that
estrogen levels might contribute to this gender-based dif-
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creased risk of coronary vascular disease has been an ex-
pected benefit of hormone replacement therapy (HRT),
and early observational studies reported decreased risk in
postmenopausal women taking HRT.4,5 More recently,
however, the validity of these findings have been chal-
lenged. Evidence indicates that HRT used for primary
prevention in healthy postmenopausal women has an ad-
verse effect on heart disease risk.6 Moreover, HRT failed to
slow the progression of atherosclerosis in postmenopausal
women with established coronary artery disease,7 and the
use of HRT has been shown to increase the risk of coronary
and thromboembolic events.8 Postmenopausal women re-
ceiving HRT have more adverse outcomes of peripheral
arterial disease and after vascular reconstruction. A previous
study from our group reports postmenopausal women tak-
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decreased primary graft patency compared to their non-
HRT counterparts.9
Intimal hyperplasia (IH) is the general response of a
vessel to injury and is considered the primary reason for late
bypass graft failure. Migration of medial vascular smooth
muscle cells (VSMCs) to the intima region plays a major
role in IH development during vessel remodeling in arterial
disorders such as atherosclerosis, hypertension, and reste-
nosis following balloon angioplasty.10,11 Additionally, es-
trogen-binding receptors have been identified on VSMCs,
consistent with the theory that this vascular function may
be under direct hormonal control.12,13 An in vivo study by
Miller et al reports that aged rats (12-months-old) given
HRT developed more IH after balloon-induced vascular
injury compared to their younger (10-week-old) female
counterparts.14
Matrix metalloproteinases (MMPs) are implicated in
vascular remodeling due to their ability to selectively de-
grade components of the extracellular matrix (ECM).15,16
VSMCs in the tunica media are surrounded by ECM that
must be degraded in order for cells to migrate through the
vascular layers. MMP-2 and -9 are considered to play a
major role in remodeling because of their ability to degrade
collagen type IV, the major component of the basement
membrane separating the vascular endothelial and medial
cell layers. MMP expression can be induced by cytokines,
growth factors, stress, or inflammation.17,18 Additionally,
we have previously shown female sex hormones affect
MMP pathways through isoform-specific mechanisms.19
MMP proteins are synthesized in their proenzyme form
and can be activated by proteolytic cleavage by other MMP
family members, such as membrane type-matrix metallo-
proteinases (MT-MMPs).20 Additionally, MMPs can be
inhibited by tissue inhibitors of MMPs (TIMPs) binding to
MMP active sites or to active MT-MMPs.21,22 A balance in
the expression and/or activity of MMPs, MT-MMPs, and
TIMPs is maintained under normal physiological condi-
tions. However, alterations within the regulatory mecha-
nism resulting in unbalanced MMP activity have been
associated with pathological remodeling.17,23,24
The present study was undertaken to examine estrogen-
and progesterone-regulated MMP expression and activity
in VSMCs, the major cell type of interest in the formation
of intimal hyperplasia and restenosis. We hypothesized that
estrogen and progesterone upregulate the MMP pathway
in VSMCs by causing an imbalance in its regulatory mech-
anism, resulting in increased matrix proteolytic degradation
and VSMC migration across ECM barriers. Understanding
hormone-regulated modifications to the critical balance of
MMP/MT-MMP/TIMP activities will enhance under-
standing of the mechanisms leading to development of
intimal hyperplasia in women receiving HRT.
MATERIALS AND METHODS
Aortic smooth muscle cell cultures. VSMCs used
in this study were human aortic smooth muscle cells
(HASMC) purchased from Cascade Biologics, Inc, Port-land, Ore. HASMCs obtained were cryopreserved primary
cultures of female single-donor cells, and their homoge-
neous nature had been confirmed through positive immu-
nocytochemical staining for -actin and negative immuno-
cytochemical staining for von Willebrands factor. The
cultures were maintained and subcultured according to the
supplier’s instructions and used between passages 4 and 8.
Because phenol red functions as a weak estrogen agonist,25
cells were cultured in phenol red-free growth medium ([5%
fetal bovine serum (FBS)/Dulbecco’s modified Eagle’s
medium (DMEM)] for 24 hours prior to beginning exper-
iments. Cells were grown to 80% confluence and made
quiescent by serum starvation for 24 hours.
Cell treatment. Cells were treated with -estradiol
(2.5-20 ng/mL; Est), progesterone (50 ng/mL; Prog), or
a hormone combination (5 ng/mL Est 50 ng/mL Prog;
Est/Prog) for 24 hours. Randomly designated groups were
maintained in their respective hormone supplemented
media and subsequently incubated for 18 hours with or
without MMP inhibitor doxycycline (40 g/mL; Doxy).
Cells from these treatment groups were used to measure
protein levels and enzymatic activity of various members
of the MMP family as well as smooth muscle cell migra-
tion. A flow chart diagramming the methods and various
cell treatment arms of the study can be found in Fig 1. All
other reagents were purchased from Sigma-Aldrich, St.
Louis, Mo.
Western blot analyses. Total cell lysates were pre-
pared in cell lysis buffer (Cell Signaling Technology, Dan-
vers, Mass), and protein contents were measured using the
BCA protein assay (Pierce, Rockford, Ill). Equal amounts
Fig 1. Schematic diagram depicting treatment timelines for each
study arm. DMEM, Dulbecco’s modified Eagle’s medium; FBS,
fetal bovine serum; BSA, bovine serum albumin; Est, estrogen;
Prog, progesterone; Doxy, doxycycline.of proteins were resolved by 10% sodium dodecyl sulfate
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trophoretically transferred to nitrocellulose membranes.
After blocking, the membranes were probed with anti-
MT1-MMP (Chemicon International, Temecula, Calif),
anti-MMP-2, anti-MMP-9, anti-TIMP-2 (Calbiochem, La
Jolla, Calif), or anti--actin antibodies (Sigma-Aldrich, St.
Louis, Mo). The membranes were then incubated with
appropriate secondary antibodies, and immune complexes
were detected using chemiluminescence and autoradiogra-
phy. Band intensities were quantified by densitometry and
normalized to -actin as a loading control.
In-gel zymography. MMP activities were measured in
conditioned media using in-gel protease analysis by Novex
(Invitrogen Co, Carlsbad, Calif). Briefly, the conditioned
media were lyophilized, and the pellets were resuspended in
water. The concentrated proteins were electrophoresed under
non-reducing conditions into 10% SDS-PAGE gels poly-
merized with 1 mg/mL gelatin. Following electrophoresis,
the gels were washed in renaturing buffer and incubated
overnight at 37°C in developing buffer. The gels were then
stained by Simply Blue SafeStain (Invitrogen Co) and
destained with water. Unstained, digested regions repre-
sent areas of MMP activity. These translucent bands were
quantified by densitometry.
Cell migration. VSMC migration was evaluated us-
ing 24-well Transwell migration chambers with 8.0 m
pore polycarbonate filter inserts (Corning, Inc, Lowell,
Mass). The inserts were coated with 50 g/mL collagen
type IV (BD Biosciences, Bedford, Mass) in 0.05N HCl
overnight at room temperature, and rehydrated with
0.1% bovine serum albumin (BSA)/DMEM). Hormone-
treated VSMCs were counted and reseeded on the inserts
at 105 cells/100 l 0.1% BSA/DMEM in the presence or
absence of Doxy. In the lower chambers, 10% FBS/
DMEM served as the chemoattractant. After 8 hours at
37°C and 5% CO2 the non-migrated cells were removed
and the migrated cells on the lower side of the filters were
fixed and stained with Dif-Quick stain (Dade Behring,
Inc, Deerfield, Ill). Migration was quantified by count-
ing the stained cells in three random fields per membrane
at 40X magnification.
Statistical analysis. All data are reported as mean 
SEM. Statistical analyses were performed using Student’s
t test or one-way ANOVA and a post-hoc Tukey’s test.
Probability (P) values of  .05 were considered to be
significant.
RESULTS
Estrogen affects MMP-2 production in a concentra-
tion-dependent manner. Cells were treated with estrogen
concentrations ranging from 2.5-20 ng/mL for 24 hours. An
increase in MMP-2 protein levels was evident at 5 ng/mL (Fig
2). Typical estrogen: progesterone levels for premenopausal
women prior to ovulation are at a ratio of 1:10.26 HRT is
commonly prescribed at this ratio to postmenopausal women
to reduce side effects and risks accompanying menopause.
Given our objective to investigate hormonally-stimulated
effects on MMPs at a translational level, we chose hormonecombination conditions (Est 5 ng/mL Prog 50 ng/mL)
that maintained this relevant estrogen/progesterone ratio.
Hormone stimulation increases MT1-MMP and
MMP-2 protein levels with no effect on TIMP-2. We
have recently reported that estrogen and progesterone dif-
ferentially regulate VSMCs MMP gene expression via iso-
form-specific mechanisms.19 RT-PCR analyses of total ri-
bonucleic acid (RNA) indicated Est increases MT1-MMP
mRNA levels independent of inflammatory cascade signal-
ing or the presence of inflammatory cytokines. Here, to
more closely examine hormonal effects on MMP family
protein production, VSMCs were treated with individual
and combination hormones as previously described. West-
ern blot analyses of highly homogenized cell lysates con-
firmed an increase in basal MT1-MMP expression at the
protein level in response to estrogen (percent increase vs
control; Est, 31  11* [*P  .05 vs control; n  3; Fig 3,
A]). Furthermore, Western blot analyses of total cell lysates
indicated an increase in basal MMP-2 protein levels in
response to both estrogen and estrogen/progesterone
combination (percent increase vs control; Est, 47  5%*;
Est/Prog, 31  10%* [*P  .05 vs control; n  4; Fig 3,
A]). As expected, doxycycline had no significant inhibitory
effect on MT1-MMP or MMP-2 protein levels (P  NS vs
control; n  3-4; Fig 3, A). There was no significant
difference among the hormone groups. Furthermore,
Western blot analyses indicated no significant change in
TIMP-2 protein levels in any group (Fig 3, B). No VSMC-
produced MMP-9 protein was detectable by Western blot
analyses, while an MMP-9 positive control source pro-
duced a readily visible signal (data not shown).
Hormone stimulation increases MMP-2 activity.
In-gel zymographic analysis was used to examine hormon-
ally regulated enzymatic activity. Estrogen and combina-
tion hormone treatment resulted in increases in basal
MMP-2 activity (percent increase vs control; Est, 27 
5%*; Est/Prog, 46 6%* [*P .05 vs control; n 4; Fig
4]). There was no significant difference among the hor-
mone groups. As expected, doxycycline significantly inhib-
ited MMP-2 activity (percent decrease vs control; Doxy, 47
 10%* [*P 0.05 vs control; n 4; Fig 4]). We were not
able to detect basal or hormonally stimulated MMP-9
enzymatic activity. Hormone treatment did not affect the
presence of MMP-2/TIMP-2 complex in reverse zymo-
gram (data not shown), further confirming hormones do
Fig 2. Determination of optimal hormone concentration. Vascu-
lar smooth muscle cells (VSMCs) were treated with the indicated
concentrations of estrogen (Est) for 24 hours. Total cell lysates
were analyzed by Western blot analysis using anti-matrix metallo-
proteinase (MMP)-2 antibodies in order to determine the mini-
mum concentration resulting in upregulation of MMPs.not have counter-regulatory effect on TIMP-2.
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through a collagen type IV lattice. To examine the func-
tional effects of Est and Prog on VSMC migration, we used a
modified Boyden chamber assay. Est significantly increased
VSMC migration across the membrane by 45 14%* (*P.05 vs control; n  3; Fig 5). Interestingly, combination
hormone treatment (Est  Prog) resulted in no significant
difference. Doxycycline inhibited both basal and Est-induced
cell migration (percent decrease vs control; Doxy, 60 16%#;
EstDoxy, 42 17%‡; #P 0.05 vs control; ‡P 0.05 vs
Est; n 3; Fig 5).
DISCUSSION
The incidence of both cardiovascular disease and non-
cardiac vascular disease is greater in men compared with
age-matched premenopausal women.2,3 Women develop
both pathologies later in life. This difference has been
attributed to the protective effect of female estrogen hor-
4™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™
Fig 3. Hormone stimulation increases membrane type 1-MMP
(MT1-MMP) and MMP-2 protein levels with no corresponding
increase in tissue inhibitors of metalloproteinase (TIMP)-2. Vas-
cular smooth muscle cells (VSMCs) were pretreated with estrogen
(5 ng/mL; Est) with (Est/Prog) and without progesterone (50
ng/mL; Prog) for 24 hours followed by doxycycline (40 g/mL;
Doxy) for 18 hours. Total cell lysates were analyzed by Western
blot using anti-MT1-MMP, anti-MMP-2, and anti-TIMP-2 anti-
bodies. A and B demonstrate representative images from 3 or 4
independent experiments. The graph exhibits the mean data 
SEM for MT1-MMP and MMP-2 protein levels. All values have
Fig 4. Hormone stimulation increases matrix metalloproteinase
(MMP)-2 activity. Vascular smooth muscle cells (VSMCs) were
pretreated with estrogen (5 ng/mL; Est) with (Est/Prog) and
without progesterone (50 ng/mL; Prog) for 24 hours followed by
doxycycline (40 g/mL; Doxy) for 18 hours. Concentrated con-
ditioned media were used to measure matrix metalloproteinase
(MMP)-2 activity using gelatin in-gel zymography. The lower
panel exhibits the mean data SEM. *P .05 vs control (C); n
3-4.been normalized with -actin *P  .05 vs control (C); n  4.
Est; n  3. HASMC, human aortic smooth muscle cells.
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hypothesis that estrogen levels might contribute to this
gender-based difference by providing “vascular protection”
has recently been challenged. Postmenopausal women re-
ceiving HRT have more adverse outcomes of peripheral
arterial disease and after vascular reconstruction. It has been
reported that HRT is an independent predictor of de-
creased primary graft patency.9 The effect of HRT on
vascular remodeling may be playing a central role in the
gender-related differences seen with atherosclerotic pro-
gression and outcomes.
Dysfunctional remodeling underlies the pathogenesis
of major vascular diseases, such as atherosclerosis and reste-
nosis.24 The progression of these diseases may be halted by
restoring balance to the processes involved in remodeling
of the ECM. A key group of enzymes involved in these
processes are MMPs, implicated in vascular remodeling due
to their ability to selectively degrade components of the
ECM.15,16 Additionally, it has been reported that increased
expression of active MMPs within plaques may contribute
to plaque rupture, hemorrhage, and aneurysm forma-
tion.23,27 Rigorous regulation of MMP production and
activity is a crucial part of ECM homeostasis.
Here we studied the effect of estrogen and progester-
one exposure on MMPs synthesized by VSMCs. In this
study, we confirm that estrogen enhances the release of
MMP-2 from vascular smooth muscle cells.27 Natoli et al
have shown that female sex steroids reduced collagen dep-
osition in human aortic smooth muscle cells, but were
unable to demonstrate an effect on MMP-2 gene or protein
expression with any sex steroid.28 The effect of hormone
exposure on the MMP pathway can be further explained
based on these and previous results. Hormone exposure
increases MT1-MMP at the transcriptional level, without a
counter-regulatory effect on TIMP-2 expression,19 ulti-
mately leading to unbalanced MMP regulation. Liao et al
have found similar results in other tissues, demonstrating
estrogen-induced upregulation of MT1-MMP expression
in human osteoblasts.29 Here, hormone exposure resulted
in increased MMP-2 enzymatic activity and increased cell
migration through a collagen IV barrier. Based on our
results and previous reports that MT1-MMP initiates the
activation of MMP-2,20 we propose that this hormonally
stimulated upregulation of MMP-2 enzymatic activity is
regulated by increased MT1-MMP expression. To examine
if hormonally-stimulated increased cell migration could
be reversed by inhibiting increased activity of MMP-2,
VSMCs were exposed to doxycycline, a known inhibitor of
MMP activity. Doxycycline significantly decreased VSMC
migration, as well as MMP-2 activity independent of RNA
or protein levels. Collectively these data support that hor-
monally stimulated increases in VSMC migration occur via
increased collagenase activity, primarily MMP-2.
There were some unanticipated outcomes of the study.
First, there was no significant difference in the increase in
MMP-2 activity between estrogen alone or in combination
with progesterone, indicating MMP upregulation may be aFig 5. Hormone stimulation induces migration of vascular
smooth muscle cells (VSMCs). The ability of cells to migrate
through a collagen type IV lattice was assessed using a modified
Boyden chamber assay. VSMCs were pretreated with estrogen with
and without progesterone (Est, 5 ng/mL; Prog, 50 ng/mL) for
24 hours. Cells were seeded on porous membranes with or without
doxycycline (40 g/mL; Doxy) for an additional 8 hours. A,
demonstrates representative images from three independent exper-
iments. Cell migration was quantified by counting the number of
migrated cells present on the lower surface in three random fields
per membrane at 40X magnification. B, represents the mean data 
SEM. *P .05 vs control (C); #P .05 vs control (C); ‡P .05 vsgeneral phenomenon of estrogen availability. Progesterone
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other cell types and pathologies.30,31 Further investigation
is needed to understand the effects of progesterone in
combination with estrogen and their individual and com-
bined influence in vascular pathology. Secondly, our study
was unable to demonstrate an upregulation of MMP-9,
most likely due to the negligible amounts of MMP-9 found
in normal aortic tissue. MMP-2 is constitutively expressed
in VSMC, whereas MMP-9 is sequestered in neutrophils,
macrophages, and other inflammatory cells. In vivo the
presence of MMP-9 in aortic tissue is primarily due to
macrophage infiltration during inflammation,23 making
MMP-9 evaluation in isolated aortic smooth muscle cells
difficult at best.
Our working hypothesis formulated from the current
study is that inhibition of MT1-MMP expression will result
in inhibition of hormonally-stimulated MMP-2 activation
and downstream effectors such as migration. In vitro stud-
ies of targeted silencing in this proposed MT1-MMP/
MMP-2 pathway are currently ongoing in our laboratory.
Blockade of estrogen receptors using specific receptor an-
tagonists alone and in combination with hormones are
being used to verify changes in MT1-MMP expression and
MMP-2 activity are a direct result of receptor signaling
prior to silencing. In addition, in vivo studies of vascular
injury in subjects exposed to HRT are needed to assay the
benefits of this approach as well. Alternatively, the uroki-
nase pathway is a known mechanism of MMP activation
and has been shown to play an important role in vascular
remodeling.32 Urokinase plasminogen activator (uPA) –
uPA receptor (uPAR) signaling converts plasminogen to
plasmin, which can in turn activate proMMP to active
MMP. An alternative hypothesis for future investigation is
that estrogen stimulated increases in MMP-2 activity occur
via this uPA-uPAR signaling mechanism.
In conclusion, in the present study we have provided
strong supportive evidence for a regulatory role of MT1-
MMP in increased migration of VSMC exposed to estrogen
and progesterone, mediated by an increase in MMP-2
activity. We previously demonstrated that hormone stimu-
lation increases MT1-MMP mRNA expression, with no
effect on MMP-2 or TIMP-2. Here hormone stimulation
increases MT1-MMP and MMP-2 protein levels with no
effect on TIMP-2. This further confirms estrogen and
progesterone are not involved in TIMP-regulated MMP
inhibition, leaving hormonally stimulated upregulation of
MMP unbalanced. Collectively, the downstream effect of
hormone stimulation results in increasing MMP-2 enzy-
matic activity. This may play a major role in the develop-
ment of intimal hyperplasia because of VSMCs ability to
degrade collagen type IV, allowing for migration and inti-
mal thickening.
The clinical implication of our findings rests in the fact
that broad, non-specific inhibition of MMPs may not result
in a decrease of intimal hyperplasia in females receiving
HRT. Overarching inhibition of the MMP pathway
(ie, TIMPs, MT-MMPs, and MMPs) likely results in
unbalanced MMP activity. Understanding the hormone-regulated modifications to the balance of MMP/MT-
MMP/TIMP activity could lead to the development of
more specific therapeutic options for postmenopausal pa-
tients with vascular disease undergoing interventions. Spe-
cifically targeting MT1-MMP expression at the time of
vascular interventions in females receiving HRT may result
in better outcomes. It has been postulated that timing of
exposure to HRT in regard to the development of athero-
sclerotic lesions and subsequent interventions may be re-
sponsible for the differential response to local injury in
previously diseased vessels. However, this variable cannot
be controlled in most cases, as atherosclerotic disease is a
continuous process and interventions may be necessary
while the patient is receiving HRT. Therefore, alternative
approaches, such as tissue targeted gene therapy need to be
examined.
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